111 related articles for article (PubMed ID: 18854802)
21. [Use of yasmin in the treatment of women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Ivancheva Kh; Amaliev I
Akush Ginekol (Sofiia); 2006; 45(3):25-9. PubMed ID: 16889184
[TBL] [Abstract][Full Text] [Related]
22. Normalization of hyperinsulinemia by chronic opioid receptor blockade in hyperandrogenemic women.
Hadziomerović D; Rabenbauer B; Wildt L
Fertil Steril; 2006 Sep; 86(3):651-7. PubMed ID: 16901484
[TBL] [Abstract][Full Text] [Related]
23. Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Tuğrul S; Kutlu T; Pekin O; Bağlam E; Kiyak H; Oral O
Fertil Steril; 2008 Oct; 90(4):1144-8. PubMed ID: 18377903
[TBL] [Abstract][Full Text] [Related]
24. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
25. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
26. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome.
Kulshreshtha B; Ganie MA; Praveen EP; Gupta N; Lal Khurana M; Seith A; Dwivedi SN; Kumar G; Ammini AC
Gynecol Endocrinol; 2008 Nov; 24(11):637-43. PubMed ID: 19031221
[TBL] [Abstract][Full Text] [Related]
27. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.
Soares GM; Vieira CS; de Paula Martins W; Dos Reis RM; de Sá MF; Ferriani RA
Int J Clin Pract; 2009 Jan; 63(1):160-9. PubMed ID: 18795969
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome.
Romualdi D; Giuliani M; Draisci G; Costantini B; Cristello F; Lanzone A; Guido M
Fertil Steril; 2007 Jul; 88(1):131-8. PubMed ID: 17336978
[TBL] [Abstract][Full Text] [Related]
29. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
[TBL] [Abstract][Full Text] [Related]
30. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Gen R; Akbay E; Muslu N; Sezer K; Cayan F
Gynecol Endocrinol; 2009 Apr; 25(4):241-5. PubMed ID: 19408173
[TBL] [Abstract][Full Text] [Related]
31. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
32. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications.
Nardo LG; Patchava S; Laing I
Panminerva Med; 2008 Dec; 50(4):267-78. PubMed ID: 19078868
[TBL] [Abstract][Full Text] [Related]
33. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin.
Vaikkakara S; Al-Ozairi E; Lim E; Advani A; Ball SG; James RA; Quinton R
Gynecol Endocrinol; 2008 Feb; 24(2):87-92. PubMed ID: 18210332
[TBL] [Abstract][Full Text] [Related]
34. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
35. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Diamanti-Kandarakis E; Economou FN; Livadas S; Tantalaki E; Piperi C; Papavassiliou AG; Panidis D
Kidney Blood Press Res; 2009; 32(1):24-31. PubMed ID: 19212122
[TBL] [Abstract][Full Text] [Related]
36. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters.
Mitkov M; Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2008 Nov; 24(11):625-30. PubMed ID: 19031219
[TBL] [Abstract][Full Text] [Related]
37. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia.
Cho LW; Kilpatrick ES; Jayagopal V; Diver MJ; Atkin SL
Clin Endocrinol (Oxf); 2008 Mar; 68(3):390-4. PubMed ID: 17888022
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
Musacchio MC; Cappelli V; Di Sabatino A; Morgante G; De Leo V
Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
[TBL] [Abstract][Full Text] [Related]
39. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS
J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914
[TBL] [Abstract][Full Text] [Related]
40. Use of antiandrogens as therapy for women with polycystic ovary syndrome.
Moghetti P
Fertil Steril; 2006 Jul; 86 Suppl 1():S30-1. PubMed ID: 16798285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
